Destiny Pharma plc (LON:DEST – Get Free Report)’s stock price traded down 30.1% during mid-day trading on Wednesday . The company traded as low as GBX 2.55 ($0.03) and last traded at GBX 3 ($0.04). 4,179,453 shares were traded during mid-day trading, an increase of 484% from the average session volume of 715,908 shares. The stock had previously closed at GBX 4.29 ($0.06).
Analyst Upgrades and Downgrades
Separately, Shore Capital reiterated a “house stock” rating on shares of Destiny Pharma in a research report on Monday, July 15th.
View Our Latest Analysis on DEST
Destiny Pharma Price Performance
Insider Buying and Selling
In related news, insider Nigel Rudd bought 1,240,000 shares of the business’s stock in a transaction on Friday, August 2nd. The stock was acquired at an average cost of GBX 0.25 ($0.00) per share, with a total value of £3,100 ($4,048.05). 25.94% of the stock is currently owned by company insiders.
About Destiny Pharma
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.
See Also
- Five stocks we like better than Destiny Pharma
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What is the Euro STOXX 50 Index?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- How to Invest in the FAANG Stocks
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.